Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies br
Ying Huang,Martin Sendzik,Jeff Zhang,Zhenting Gao,Yongfeng Sun,Long Wang,Justin Gu,Kehao Zhao,Zhengtian Yu,Lijun Zhang,Qiong Zhang,Joachim Blanz,Zijun Chen,Valérie Dubost,Douglas Fang,Lijian Feng,Xingnian Fu,Michael Kiffe,Ling Li,Fangjun Luo,Xiao Luo,Yuan Mi,Prakash Mistry,David Pearson,Alessandro Piaia,Clemens Scheufler,Remi Terranova,Andreas Weiss,Jue Zeng,Hailong Zhang,Jiangwei Zhang,Mengxi Zhao,Michael P Dillon,Sebastien Jeay,Wei Qi,Jonathan Moggs,Carole Pissot-Soldermann,En Li,Peter Atadja,Andreas Lingel,Counde Oyang JOURNAL OF MEDICINAL CHEMISTRY（2022）
关键词
selective prc2 inhibitor,clinical candidate mak683,advanced malignancies,eed-directed
AI 理解论文
溯源树
样例
